SEE ALSO...
Items 11 to 15 of 15 total
Display:
Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
---|---|---|---|---|---|---|
Pirenzepine Dihydrochloride | 29868-97-1 | sc-204197 | 100 mg | $69.00 | 3 | |
Pirenzepine is a selective mAChR M4 antagonist that exerts its inhibitory effects by binding specifically to the receptor. By doing so, it interferes with the normal binding of acetylcholine, disrupting downstream signaling pathways. This interference can modulate various cellular responses and physiological processes regulated by mAChR M4, providing a targeted means of inhibiting its function. | ||||||
Telenzepine dihydrochloride | 147416-96-4 | sc-204332 sc-204332A | 10 mg 25 mg | $62.00 $128.00 | ||
Telenzepine is a selective mAChR M4 antagonist that achieves inhibition by binding to the receptor and interfering with the normal binding of acetylcholine. This interference disrupts downstream signaling pathways associated with mAChR M4, influencing neurotransmission and cellular responses that depend on the proper functioning of this receptor. | ||||||
Ipratropium bromide | 22254-24-6 | sc-203606 | 100 mg | $83.00 | 3 | |
Ipratropium bromide acts as an mAChR M4 antagonist, disrupting receptor function by competitively binding to its orthosteric site. This interference prevents acetylcholine from effectively binding to the receptor, leading to the modulation of downstream signaling pathways associated with mAChR M4. | ||||||
AQ-RA 741 | 123548-16-3 | sc-203517 sc-203517A | 10 mg 50 mg | $135.00 $575.00 | ||
AQRA 741 is a selective mAChR M4 antagonist that achieves inhibition by binding to the receptor and interfering with the binding of acetylcholine. This interference disrupts downstream signaling pathways associated with mAChR M4, modulating cellular responses and physiological processes that depend on the normal functioning of this receptor. | ||||||
Pilocarpine | 92-13-7 | sc-479256 | 100 mg | $250.00 | 1 | |
Pilocarpine, an alkaloid, acts as an indirect inhibitor of mAChR M4 by stimulating muscarinic receptors, particularly M1 and M3, leading to increased acetylcholine release. The subsequent activation of these receptors results in negative feedback mechanisms that inhibit the release of acetylcholine at the M4 receptor. |